Synthesis of Biodegradable Nanospheres for Side-Effect-Free Anti-Cancer Drug Delivery (2007) Nicholas Derrico
1 Background Cancer causes 13% of all deaths worldwide
2 Background Cancer has no cure
3 Background Cancer causes 13% of all deaths worldwide Cancer has no cure-all Chemotherapy dissolves highly toxic drugs into hydrophobic solutions, which are then administered to the patient, killing cells indiscriminately.
4 Purpose To develop a cutting-edge, side-effect-free delivery system to encapsulate camptothecin in biodegradable, biocompatible nanospheres that will target only cancer cells
5 Background Cancer cells have leaky vasculature
6 Background Cancer cells have leaky vasculature <200 nm
7 Previous Studies Sheihet (2007) successfully encapsulated the drug paclitaxel
8 Previous Studies Sheihet (2007) successfully encapsulated the drug paclitaxel Gounder (2007) used biodegradable, biocompatible nanospheres to kill cancer in mice without side-effects
9 Goals To synthesize nanospheres from ABA- triblock copolymers that are < 200 nm in hydrodynamic diameter
10 Goals To synthesize nanospheres from ABA- triblock copolymers that are < 200 nm in hydrodynamic diameter To determine the composition of ABA- triblock copolymers that will form nanospheres that can hold as much camptothecin as possible
11 ABA-Triblock Copolymer Biodegradable
12 ABA Triblock Copolymer Biodegradable Biocompatible
13 ABA Triblock Copolymer Biodegradable Biocompatible Non-cytotoxic
14 ABA Triblock Copolymer Biodegradable Biocompatible Non-cytotoxic Spontaneously self-assemble into nanospheres in aqueous solution
15 B-Block
16 Desaminotyrosyl Tyrosine Alkyl Ester
17 Desaminotyrosyl Tyrosine Alkyl Ester R = Pendant Chains
18 Desaminotyrosyl Tyrosine Butyl Ester
19 Desaminotyrosyl Tyrosine Octyl Ester
20 Desaminotyrosyl Tyrosine Dodecyl Ester
21 Desaminotyrosyl Tyrosine Benzyl Ester
22 Desaminotyrosyl Tyrosine Alkyl Ester
23 Suberic Acid
24 B-Block
25 Poly(ethylene glycol) = A-Block
26 Self-Assembling into Nanospheres B-Block A-Block
27 Self-Assembling into Nanospheres
28 Self-Assembling into Nanospheres
29 Self-Assembling into Nanospheres =
30 Self-Assembling into Nanospheres
31 Self-Assembling into Nanospheres
32 Self-Assembling into Nanospheres
33 Self-Assembling into Nanospheres
34
35 Self-Assembling into Nanospheres
36 Compositions CopolymersRatios DTB-SA/5K100% DTO-SA/5K100% DTD-SA/5K100% DTBn-SA/5K100% DTB-SA/5K + DTO-SA/5K50%-50% DTB-SA/5K + DTD-SA/5K50%-50% DTB-SA/5K + DTBn-SA/5K50%-50% DTB-SA/5K + DTO-SA/5K DTD-SA/5K + DTBn-SA/5K 25%-25%
37 Compositions CopolymersRatios DTB-SA/5K100% DTO-SA/5K100% DTD-SA/5K100% DTBn-SA/5K100% DTB-SA/5K + DTO-SA/5K50%-50% DTB-SA/5K + DTD-SA/5K50%-50% DTB-SA/5K + DTBn-SA/5K50%-50% DTB-SA/5K + DTO-SA/5K DTD-SA/5K + DTBn-SA/5K 25%-25%
38 Camptothecin Only Nanospheres Results
39 Camptothecin Only Nanospheres Results
40 Figure 5: VD3 Binding Efficiency of 3 best copolymer compositions Binding Efficiencies of Vitamin D3
41 Figure 4: CPT Binding Efficiency of 3 best copolymer compositions Binding Efficiencies of Camptothecin
42 Conclusion 15% camptothecin was encapsulated
43 Conclusion 15% camptothecin was encapsulated Pelleting occurred during ultracentrifugation
44 Future Study Use ultrafiltration in procedure
45 Acknowledgements Team Research Larisa Sheihet Ph.D Will Mallon Ms. Lois Fruen
46 Questions?
Synthesis of Biodegradable Nanospheres for Side-Effect-Free Anti-Cancer Drug Delivery (2007) Nicholas Derrico